Denali Therapeutics Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
$0
R&D↓-1.9% -$2M
$98M
D&A↑+54.7% +$1M
$3M
Operating Income↓-11.6% -$14M
$-137M
EBITDA↑+54.7% +$1M
$3M
Tax Provision↑+50.0% +$34K
$102K
Net Income↓-18.4% -$20M
$-127M
Operating Margin
—
Net Margin
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.3pts
-0.3%
ETR Foreign Differential (pp)↑+0.0pts
0.0%
Operating Lease Cost↑+36.4% +$506K
$2M
Revenue YoY Variation
-100.0%
Income YoY Variation↓-3.3pts
-11.6%
Revenue QoQ Variation
—
Income QoQ Variation↑+3.8pts
-1.8%